Resources | NITAG RESOURCE CENTER

2023 ∙ STIKO

Decision on the implementation of the COVID-19 vaccination into the general recommendations of the STIKO 2023

2023 ∙ ATAGI

ATAGI recommendations on use of the Moderna and Pfizer monovalent Omicron XBB.1.5 COVID-19 vaccines

2023 ∙ ATAGI

ATAGI Update on the COVID-19 Vaccination Program

2023 ∙ ATAGI

ATAGI advice on the preferential use of bivalent COVID-19 vaccines for primary vaccination of people aged 12 years or older

2023 ∙ ATAGI

ATAGI 2023 booster advice

2023 ∙ ATAGI

ATAGI recommendations on use of the Pfizer bivalent (Original/Omicron BA.4/5) COVID-19 vaccine

2022 ∙ ATAGI

ATAGI recommendations on use of the Pfizer bivalent (Original/Omicron BA.1) COVID-19 vaccine

2022 ∙ ATAGI

ATAGI recommendations for a booster dose of the paediatric Pfizer COVID-19 vaccine in children aged 5 to 11 years

2022 ∙ ATAGI

COVID-19 vaccination – Guidance on myocarditis and pericarditis after COVID-19 vaccines

2022 ∙ ATAGI

ATAGI statement on use of the Moderna bivalent Original/Omicron vaccine